Psychosis in Parkinson's disease

被引:70
|
作者
Poewe, W [1 ]
机构
[1] Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria
关键词
Parkinson's disease; psychosis; atypical neuroleptics; hallucination; cholinesterase inhibitors;
D O I
10.1002/mds.10566
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Psychosis is a disabling nonmotor complication of Parkinson's disease (PD). Visual hallucinations are the most common clinical manifestation and have been observed in up to 40% of patients with advanced disease in hospital-based series. Age, cognitive dysfunction, depression, as well as severity and duration of disease have all been identified as risk factors in multiple studies. All major anti parkinsonian drugs can induce psychosis in at-risk patients. Early drug-induced psychosis has been observed in up to 16% of patients treated with dopamine agonists and has been associated with increased risk for the development of dementia later on. Management of psychosis in PD is complex and includes control of potential triggers and reductions of polypharmacy as well as the addition of atypical antipsychotics. Cholinesterase inhibitors may prove an additional option in psychotic PD patients with dementia. (C) 2003 Movement Disorder Society.
引用
收藏
页码:S80 / S87
页数:8
相关论文
共 50 条
  • [21] Management of psychosis in Parkinson's disease
    D'Souza, C
    Gupta, A
    Alldrick, MD
    Sastry, BSD
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2003, 57 (04) : 295 - 300
  • [22] Psychosis in Prodromal Parkinson's disease
    Pachi, I.
    Maraki, M.
    Kosmidis, M.
    Yannakoulia, M.
    Dardiotis, E.
    Hadjigeorgiou, G.
    Sakka, P.
    Xiromerisiou, G.
    Stamelou, M.
    Scarmeas, N.
    Stefanis, L.
    MOVEMENT DISORDERS, 2019, 34 : S154 - S154
  • [23] Managing psychosis in Parkinson's disease
    Friedman, Joseph H.
    NEURODEGENERATIVE DISEASE MANAGEMENT, 2011, 1 (03) : 217 - 226
  • [24] Epidemiology of psychosis in Parkinson's disease
    Fenelon, Gilles
    Alves, Guido
    JOURNAL OF THE NEUROLOGICAL SCIENCES, 2010, 289 (1-2) : 12 - 17
  • [25] Psychosis and depression in Parkinson's disease
    Brandstädter, D
    Oertel, WH
    PARKINSON'S DISEASE, 2002, 1 : 29 - 38
  • [26] Parkinson psychosis rating scale: A practical instrument for grading psychosis in Parkinson's disease
    Friedberg, G
    Zoldan, J
    Weizman, A
    Melamed, E
    CLINICAL NEUROPHARMACOLOGY, 1998, 21 (05) : 280 - 284
  • [27] Pimavanserin for the treatment of Parkinson's disease psychosis
    Friedman, Joseph H.
    EXPERT OPINION ON PHARMACOTHERAPY, 2013, 14 (14) : 1969 - 1975
  • [28] PSYCHOSIS IN PARKINSON'S DISEASE: THERAPEUTIC OPTIONS
    Hasnain, M.
    DRUGS OF TODAY, 2011, 47 (05) : 353 - 367
  • [29] Antipsychotics for the management of Parkinson's disease psychosis
    Jethwa, Ketan Dipak
    INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY, 2017, 32 (04) : 464 - 465
  • [30] Psychopharmacologic management of psychosis in Parkinson's Disease
    Quitangon, GD
    Rosales-Eder, L
    BIOLOGICAL PSYCHIATRY, 2003, 53 (08) : 41S - 42S